TSC-100 is under clinical development by TScan Therapeutics and currently in Phase I for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). According to GlobalData, Phase I drugs for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TSC-100’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TSC-100 overview
TSC-100 is under development for the treatment of blood cancers like acute myelocytic Leukemia, acute lymphocytic leukemia and myelodysplastic syndrome in patients receiving hematopoietic stem cell transplant therapy with the goal of preventing relapse, a high unmet need in this setting. It acts by targeting HA-1 antigen. The therapeutic candidate comprises of T cells engineered to express a TCR of interest which are mixed with a genome-wide library of target cell. The drug candidate is developed based on the TScan platform technology. It is administered by intravenous route.
See Also:
TScan Therapeutics overview
TScan Therapeutics (TCR) provides life-changing T cell therapies for patients. It is headquartered in Boston, Massachusetts, the US.
For a complete picture of TSC-100’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
